Pfizer's Xeljanz meets goals in ulcerative colitis trials

(Reuters) - Pfizer Inc said on Friday its Xeljanz rheumatoid arthritis drug succeeded in meeting primary and secondary goals of a pair of late stage clinical trials in ulcerative colitis, results that could help pave the way for an additional approval for the oral medicine.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro